I-131 Meta Iodobenzylguanidine Therapy
Radiolabelled meta-iodobenzylguanidine (mIBG) has been used to treat neuroectodermal tumours since 1983 (Sisson et al. 1983). mIBG therapy has evolved slowly reflecting both the rarity of neuroectodermal tumours and the limited number of specialist facilities equipped to deliver treatment safely. Published series demonstrate considerable experience using this approach but, to date, few randomised controlled trials have been undertaken. As most centres developed treatment protocols tailored to local practice and expertise, direct comparison of results between institutions is difficult. Reports of treatment efficacy are, therefore, often based upon retrospective review of single centre experience.
This review will summarise the rationale for mIBG therapy, treatment indications, patient selection criteria, toxicity and prospects for future development.
Cellular mIBG uptake occurs by two distinct mechanisms (Smets et al. 1989). The dominant pathway is...
KeywordsMedullary Thyroid Cancer mIBG Uptake 131I mIBG Symptom Palliation Bone Marrow Reserve
- Altman A, Kissel M, Zitzmann K et al (2003) Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 44:973–980Google Scholar
- De Souza JA, Busaidy N, Zimrin A et al. (2010) Phase II trial of sunitinib in medullary thyroid cancer. J Clin Oncol 28:15 s (suppl; abstr 5504)Google Scholar
- Dubois SG, Chesler L, Groshen S (2012) Phase I study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. Clin Cancer Res. Mar 16 EPub ahead of printGoogle Scholar
- Gaze MN, Alspach A, Biassoni L et al. (2012) 131I-meta iodobenzylguanidine and topotecan in neuroblastoma (MATIN): audit of an innovative treatment schedule in five international society of paediatric oncology –Europe neuroblastoma (SIOPEN) centres. Eur J Cancer (in press)Google Scholar
- Hoefnagel CA, Lewington VJ (2004) mIBG therapy. In: Ell PJ, Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edn). Churchill Livingstone, pp 445–457Google Scholar
- Howard JP, Maris JM, Kersun LS et al. (2005) Tumor response and toxicity with multiple infusions of high dose (131)I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44:232–239Google Scholar
- Ladenstein R, Philip T, Lasset C et al (1998) Multivariate analysis of risk factors in stage IV neuroblastoma patients over the age of 1 year treated with megatherapy and stem cell transplantation: a report from the European bone marrow transplantation solid tumour registry. J Clin Oncol 16:953–965PubMedGoogle Scholar
- Mairs RJ, Boyd M (2008) Optimising MIBG therapy of neuroendocrine tumours: preclinical evidence of dose maximisation and synergy. Nucl Med Biol 35: SI:9–SI:20Google Scholar
- Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. J Clin Oncol 24:500–506PubMedCrossRefGoogle Scholar
- Mukherjee JJ, Kaltsas GA, Islam N et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglionoma,and medullary carcinoma of the thyroid with 131-I-meta-iodobenzylguanidine. Clin Endocrinol. 55:47–60Google Scholar
- Prymer DA, Barrett JA, Coleman RE et al. (2011). Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo) J Clin Oncol 29: (suppl; abstr e21122)Google Scholar
- Rutgers M, Buitenhuis CK, van der Valk MA, Hoefnagel CA, Voute PA, Smets LA (2000) [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Int J Cancer 90:312–325PubMedCrossRefGoogle Scholar
- van santen HM, de Kraker J, Vulsmer T et al. (2005) Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 1767–1774Google Scholar